These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Complications of bacillus Calmette-Guerin (BCG) immunotherapy in superficial bladder cancer. Sosnowski JT Compr Ther; 1994; 20(12):695-701. PubMed ID: 7882653 [No Abstract] [Full Text] [Related]
24. Ocular involvement following Bacillus Calmette-Guerin immunotherapy for bladder carcinoma. Cugati S; Gilhotra JS; Lake S; Gordon DL Clin Exp Ophthalmol; 2014 Jul; 42(5):494-5. PubMed ID: 24372891 [No Abstract] [Full Text] [Related]
25. Incidental detection of increased (18)F-FDG uptake and its follow-up in patients with granulomatous prostatitis after BCG treatment for urinary bladder cancer. Kim CY; Lee SW; Yoon G; Jeong SY; Ahn BC; Lee J Hell J Nucl Med; 2014; 17(3):204-7. PubMed ID: 25397626 [TBL] [Abstract][Full Text] [Related]
26. [Reiter syndrome after intravesical Bacillus Calmette-Guerin (BCG) immunotherapy: a case report]. Shiba M; Fujii T; Takatera H Hinyokika Kiyo; 2003 Oct; 49(10):599-601. PubMed ID: 14655604 [TBL] [Abstract][Full Text] [Related]
27. Tubercular disease caused by Bacillus of Calmette-Guérin as a local adjuvant treatment of relapsing bladder carcinoma. Manfredi R; Dentale N; Piergentili B; Pultrone C; Brunocilla E Cancer Biother Radiopharm; 2009 Oct; 24(5):621-7. PubMed ID: 19877893 [TBL] [Abstract][Full Text] [Related]
28. Changes observed in multiparametric prostate magnetic resonance imaging characteristics correlate with histopathological development of chronic granulomatous prostatitis after intravesical Bacillus Calmette-Guerin therapy. Logan JK; Walton-Diaz A; Rais-Bahrami S; Merino MJ; Turkbey B; Choyke PL; Pinto PA J Comput Assist Tomogr; 2014; 38(2):274-6. PubMed ID: 24637671 [TBL] [Abstract][Full Text] [Related]
29. Purulent abscess after bacillus Calmette-Guerin therapy for bladder cancer. Konrad K; Földes K J Rheumatol; 1995 Jul; 22(7):1441. PubMed ID: 7562797 [No Abstract] [Full Text] [Related]
32. Bacillus Calmette-Guerin (BCG) balanitis as a complication of intravesical BCG immunotherapy: a case report. Erol A; Ozgür S; Tahtali N; Akbay E; Dalva I; Cetin S Int Urol Nephrol; 1995; 27(3):307-10. PubMed ID: 7591595 [No Abstract] [Full Text] [Related]
33. The safety and efficacy of different doses of bacillus Calmette Guérin in superficial bladder transitional cell carcinoma. Agrawal MS; Agrawal M; Bansal S; Agarwal M; Lavania P; Goyal J Urology; 2007 Dec; 70(6):1075-8. PubMed ID: 18158020 [TBL] [Abstract][Full Text] [Related]
34. Re: Agarwal a et al.: The safety and efficacy of different doses of bacillus Calmette Guerin in superficial bladder transitional cell carcinoma (Urology 2007;70:1075-1078). Agrawal MS; Bansal S Urology; 2009 Feb; 73(2):450-1. PubMed ID: 19185768 [No Abstract] [Full Text] [Related]